Cynata Therapeutics Limited

DB:51S Stock Report

Market Cap: €24.2m

Cynata Therapeutics Valuation

Is 51S undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 51S when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 51S's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 51S's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 51S?

Key metric: As 51S is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 51S. This is calculated by dividing 51S's market cap by their current revenue.
What is 51S's PS Ratio?
PS Ratio16.8x
SalesAU$2.32m
Market CapAU$38.85m

Price to Sales Ratio vs Peers

How does 51S's PS Ratio compare to its peers?

The above table shows the PS ratio for 51S vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average6.1x
MDG1 Medigene
3x16.1%€22.6m
CNW co.don
0.7xn/a€6.5m
HPHA Heidelberg Pharma
12.3x16.6%€103.9m
2INV 2invest
8.2xn/a€63.8m
51S Cynata Therapeutics
16.8x70.4%€38.8m

Price-To-Sales vs Peers: 51S is expensive based on its Price-To-Sales Ratio (16.8x) compared to the peer average (7.8x).

Price to Sales Ratio vs Industry

How does 51S's PS Ratio compare vs other companies in the DE Biotechs Industry?

6 CompaniesPrice / SalesEstimated GrowthMarket Cap
CNW co.don
0.7xn/aUS$6.97m
V9Z Aceragen
0.4xn/aUS$3.12m
PA8 Paion
0.2x30.2%US$2.78m
V9Z Aceragen
0.3x-161.8%US$2.18m
51S 16.8xIndustry Avg. 8.1xNo. of Companies6PS0612182430+
6 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: 51S is expensive based on its Price-To-Sales Ratio (16.8x) compared to the European Biotechs industry average (8.1x).

Price to Sales Ratio vs Fair Ratio

What is 51S's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

51S PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio16.8x
Fair PS Ratio17.7x

Price-To-Sales vs Fair Ratio: 51S is good value based on its Price-To-Sales Ratio (16.8x) compared to the estimated Fair Price-To-Sales Ratio (17.7x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Aspen Pharmacare Holdings

R75.5b

Manufactures and supplies specialty and branded pharmaceutical products worldwide.

LDZA

R8.95

7D

0.6%

1Y

4.7%

Amneal Pharmaceuticals

US$2.6b

Develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide.

2DT

US$7.70

7D

-4.3%

1Y

91.5%

Almirall

€1.8b

A biopharmaceutical company, engages in the purchase, manufacture, storage, and sale of skin-health medicines in Europe, the Middle East, the United States, Asia, and Africa.

E2Z

€8.29

7D

-1.8%

1Y

0.2%